Publicaciones en las que colabora con SANTIAGO MORENO GUILLÉN (13)

2024

  1. Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159

2023

  1. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125

2021

  1. Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain

    Open Forum Infectious Diseases, Vol. 8, Núm. 7

  2. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. Gender-based vulnerability in women who inject drugs in a harm reduction setting

    PLoS ONE, Vol. 15, Núm. 3

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units

    International Journal of Drug Policy, Vol. 72, pp. 181-188

2018

  1. HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination

    PLoS ONE, Vol. 13, Núm. 10

  2. High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit: A lost opportunity for preexposure prophylaxis

    AIDS, Vol. 32, Núm. 9, pp. 1157-1163

2017

  1. Correction: Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 Week results of the SIMRIKI retrospective study (PLoS ONE (2016) 11:10 (e0164455) DOI: 10.1371/journal.pone.0164455)

    PLoS ONE

2016

  1. Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study

    PLoS ONE, Vol. 11, Núm. 10

2015

  1. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

2014

  1. A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011

    Eurosurveillance, Vol. 19, Núm. 20